Defining the In Vivo Role of mTORC1 in Thyrocytes by Studying the TSC2 Conditional Knockout Mouse Model

Camila Ludke Rossetti1, Bruna Lourençoni Alves1,2, Flavia Leticia Martins Peçanha1

  • 1Division of Endocrinology, Diabetes and Metabolism, University of Miami, Miami, Florida, USA.

Insights

Mechanistic target of rapamycin complex 1 (mTORC1) activation in thyroid cells drives thyroid gland growth and proliferation. This activation inhibits thyroid hormone biosynthesis and gene expression, effects reversed by rapamycin treatment.

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Oncology

Background:

  • Thyroid dysfunction arises from abnormal epithelial cell growth.
  • The mechanistic target of rapamycin (mTOR) pathway, including mTORC1 and mTORC2, regulates cell growth and metabolism.
  • Overactive PI3K-Akt-mTORC1 signaling is linked to aggressive thyroid cancer.

Purpose of the Study:

  • To investigate the specific role of mTORC1 in thyrocytes.
  • To develop and characterize a novel mouse model with gain-of-function mTORC1 in thyrocytes.

Main Methods:

  • Created a thyrocyte-specific mouse model (TPO-TSC2) by deleting TSC2, an mTORC1 inhibitor.
  • Assessed thyroid gland size, thyrocyte proliferation (Ki67, cyclin D3), gene expression (Tg, Tpo, Nis), and protein levels (NIS).
  • Administered the mTORC1 inhibitor rapamycin to evaluate its effects on thyroid mass and gene expression.

Main Results:

  • TPO-TSC2 mice showed significantly reduced TSC2 and increased mTORC1 activity, leading to thyroid enlargement and increased thyrocyte proliferation.
  • mTORC1 activation suppressed key thyroid hormone biosynthesis genes (Tg, Tpo, Nis) and NIS protein expression.
  • Rapamycin treatment normalized thyroid mass and gene expression in TPO-TSC2 mice.
  • While hormone levels were initially normal, TPO-TSC2 mice developed decreased T4 and increased TSH by 12 months.

Conclusions:

  • Thyrocyte-specific mTORC1 activation promotes thyroid growth and proliferation.
  • mTORC1 signaling inhibits thyroid hormone biosynthesis and thyrocyte-specific gene expression.
  • Targeting mTORC1 with rapamycin can counteract these effects, suggesting therapeutic potential.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.5K
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
5.5K